Santarus boosted by positive PhIII; Tetraphase touts PhII antibiotic data for lead program; Atox drug hits FDA's fast track;

Conversations on Twitter :

 @FierceBiotech: D-Day for Sanofi multiples cerlosis drug Aubagio as deep R&D cuts loom. Story | Follow @FierceBiotech

 @JohnCFierce: Lundbeck, Otsuka scramble to get antipsychotic back on FDA track--(competing with Alkermes). Article | Follow @JohnCFierce

 @RyanMFierce: My take on Illumina's alliance with Partners HealthCare to combine sequencing and software. Story | Follow @RyanMFierce

> Shares of Santarus were boosted after the biotech reported that its experimental treatment for traveler's diarrhea successfully beat out a placebo in Phase III. On average patients taking rifamycin SV MMX no longer suffered from diarrhea after an average of 46 hours. Patients on a placebo continued to suffer to 68 hours. Story

> 2010 Fierce 15 winner Tetraphase says its lead antibiotic delivered solid results in a mid-stage, 143-patient comparison study. In the three-arm study, which included a group of patients receiving Merck's ($MRK) Invanz and two doses of TP-434, Tetraphase says all three arms demonstrated cure rates of 93% to 100%. Watertown, MA-based Tetraphase is one of several biotechs developing new antibiotics. Release

> Israel's Atox Bio won fast-track designation from the FDA for AB103, its program to combat flesh-eating bacteria. Story

> Shares of Cell Therapeutics ($CTIC) bumped up after the U.S. biotech outlined plans to launch its cancer drug Pixuvri in several Nordic countries. Story

> Australia's Prana Biotechnology, a penny stock company, got a boost when an independent committee recommended continued work on its Alzheimer's drug PBT2. Story

Pharma News

 @FiercePharma: Sanofi workers to strike as day of reckoning nears. More | Follow @FiercePharma

> Merck's Singulair sales free-fall 90% in 4 weeks. Article

> Roche loses patent fight in India as Novartis fights on. Report

> Pfizer's Prevenar 13 gets a shot in the arm with WHO approval. Story

Medical Device News

 @FierceMedDev: J&J has settled the first three lawsuits involving failure of its ASR hip implants. Thousands more to come. Release | Follow @FierceMedDev

 @MarkHFierce: bioMerieux got slapped with an FDA warning letter for quality violations regarding a NC Dx manufacturing facility. Warning Letter | Follow @MarkHFierce

 @DamianFierce: Berkeley's Ekso Bionics is looking to expand the use of its robotic walking aid. Report | Follow @DamianFierce

> IntraPace preps anti-obesity device for U.S. regulatory path. More

> PrimeraDx snags CE marks for assays. News

Biomarkers News

> Janssen's Remicade attacks inflammation to beat depression. Article

> Increased antibody levels tag raised rheumatoid arthritis risk. Story

> Researchers develop genetic test to fine-tune warfarin dose. Item

> Breast cancer protein pinpoints survival chances. More

Drug Delivery News

> Hopkins cracks blood-brain barrier with nanobeads. More

> Sublingual opioid addiction therapy moves closer to market. Report

> Silence breaks out with preclinical data on Atu111. Story

> InSite eyes next-generation DuraSite delivery. Article

> Anti-HIV vaginal ring shows hints of efficacy. More

> AZ goes Down Under for cancer conjugate deal. Item

And Finally... MedImmune is hinting that it may expand its HQ facilities. Story

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.